




000000

تم رفع هذه الرسالة بواسطة / سنوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات:





The In Vivo Expression of Gamma Secretase Catalytic Subunit (Presenilin) in Patients with Chronic Lymphocytic Leukemia)

Thesis

Submitted for Partial Fulfillment
of Master Degree in **Internal Medicine**

By

Engy Alaa Eldin Loly Abbas

M.B.B.Ch

Under supervision of

Prof. Dr. Mohamed Osman Azzazi

*Professor of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation
Faculty of Medicine, Ain Shams University*

Prof. Dr. Amal Mostafa ElAfifi

*Professor of Internal Medicine, Clinical Hematology and Bone marrow Transplantation
Faculty of Medicine, Ain Shams University*

Prof. Dr. Nermeen Adel Nabih

*Assistant Professor of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation
Faculty of Medicine, Ain Shams University*

Dr. Verna Adib Shawky

*Lecturer of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسببائك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mohamed Osman Azzazi**, Professor of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation, Faculty of Medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Amal Mostafa ElAfifi**, Professor of Internal Medicine, Clinical Hematology and Bone marrow Transplantation, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Dr. Nermeen Adel Nabih**, Assistant Professor of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Oerna Adib Shawky**, Lecturer of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation, Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Suha Raof**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Engy Alaa Eldin Loly Abbas

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	ii
List of Abbreviations	iv
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
Chronic Lymphocytic Leukemia	5
Gamma Secretase.....	55
Gamma Secretase Inhibitors in Malignancy.....	61
Patients and Methods.....	68
Results.....	78
Discussion.....	90
Summary.....	100
Conclusion	103
Recommendations.....	104
References.....	105
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	Buffer RLT was added to pelleted leucocytes	70
Table (2):	Genomic DNA elimination reaction components	72
Table (3):	Reverse transcription master mix preparation	72
Table (4):	Comparison between the patient group and the control group using Chi -Square test as regard Age and sex	78
Table (5):	The clinical characteristics of CLL patients included in the study	79
Table (6):	The laboratory characteristics of CLL patients included in the study	79
Table (7):	The Qualitative data of CLL patients included in the study	80
Table (8):	Comparison between the patient and the control groups as regard the expression of gamma secretase catalytic subunit (presenilin 2) using Mann-Whitney test	80
Table (9):	Correlation between laboratory characteristics of CLL patients and gamma secretase catalytic subunit presenilin 2 gene expression	83
Table (10):	Correlation between expression of gamma secretase catalytic subunit presenilin2 with the major characteristics of CLL patients included in the study	84
Table (11):	Comparison between control and different types of CLL patients included in the study as regard the gamma secretase catalytic subunit presenilin2 expression using Kruskal Wallis test	86
Table (12):	Kaplan Meier analysis for overall survival of the studied patients	88
Table (13):	Kaplan Meier analysis for the relation between level of Gamma secretase and overall survival of the studied patients	89

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Typical features of CLL/SLL.	8
Figure (2):	“Small-cell” component of CLL/SLL.	8
Figure (3):	Paraimmunoblasts.....	8
Figure (4):	Richter’s syndrome.....	9
Figure (5):	Specific skin lesion.	15
Figure (6):	Mantle cell lymphoma with typical features	34
Figure (7):	Mantle cell lymphoma. This case is composed of lymphoma cells, which are almost the same size as small lymphocytes, and was difficult to distinguish from small lymphocytic lymphoma without immunohistological examination	34
Figure (8):	Lymphoplasmacytic lymphoma with MYD88 L265P.....	38
Figure (9):	Bone marrow involvement of lymphoplasmacytic lymphoma	38
Figure (10):	Suggested approach for treatment of newly diagnosed CLL.....	40
Figure (11):	A NOTCH ligand is shown occupying the extracellular portion of the NOTCH receptor molecule.....	60
Figure (12):	NOTCH signaling pathway and clinical trials with secretase inhibitors.....	64
Figure (13):	Showing that expression of presenilin2 was higher in CLL patients than control group.....	81
Figure (14):	Receiver operating characteristic curve (ROC).....	82
Figure (15):	Showing that gamma secretase catalytic subunit presently 2gene expression was higher in relapsed and resistant group in comparison to newly diagnosed group.....	85

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (16):	Showing that the gamma secretase catalytic subunit presenilin2 expression was highest in resistant relapsed group then newly diagnosed CLL patients then control group.....	87
Figure (17):	Kaplan Meier analysis for overall survival of the studied patients	88
Figure (18):	Kaplan Meier analysis for the relation between level of Gamma secretase and overall survival of the studied patients	89

List of Abbreviations

Abb.	Full term
<i>ADCC</i>	<i>Antibody dependent cell-mediated cytotoxicity</i>
<i>AEs</i>	<i>Adverse events</i>
<i>ALL</i>	<i>Acute lymphoblastic leukemia</i>
<i>AML</i>	<i>Acute myeloid leukemia</i>
<i>APP</i>	<i>Amyloid –protein precursor</i>
<i>ATM</i>	<i>Ataxia telangiectasia mutated</i>
<i>BCL2</i>	<i>B cell lymphoma 2</i>
<i>BCR</i>	<i>B cell receptor</i>
<i>CDC</i>	<i>Complement-dependent cytotoxicity</i>
<i>CLL Chronic</i>	<i>lymphocytic leukaemia</i>
<i>CLL-IPI</i>	<i>Chronic Lymphocytic Leukemia Inter national Prognostic Index</i>
<i>DDR</i>	<i>DNA damage response</i>
<i>DLBCL</i>	<i>Diffuse large B-cell lymphoma</i>
<i>EBMT</i>	<i>European Society for Blood and Marrow Transplan tation</i>
<i>EMA</i>	<i>European Medicines Agency</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>GS</i>	<i>Gamma-secretase</i>
<i>GSI</i>	<i>Secretase inhibitors</i>
<i>HCT-CI</i>	<i>Hematopoietic Cell Transplantation-Specific Comorbidity Index</i>
<i>HSV</i>	<i>Herpes simplex virus</i>
<i>IC</i>	<i>Inhibitory concentration</i>
<i>ICD</i>	<i>Intracellular domain</i>
<i>IGHV</i>	<i>Immunoglobulin heavy-chain genes</i>
<i>LPL</i>	<i>Lymphoplasmacytic lymphoma</i>
<i>MALT</i>	<i>Mucosa-associated lymphoid tissue</i>
<i>MBL Monoclonal</i>	<i>B-cell lymphocytosis</i>
<i>MCL</i>	<i>Mantle cell lymphoma</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>MRD</i>	<i>Minimal residual disease</i>
<i>MZL</i>	<i>Marginal zone B-cell lymphoma</i>
<i>NCT</i>	<i>Nicestrin</i>
<i>NGS</i>	<i>Next generation sequencing</i>
<i>NICD</i>	<i>Releases the NOTCH intracellular domain</i>
<i>NIH</i>	<i>National Institutes of Health</i>
<i>NRM</i>	<i>Non relapse mortality</i>
<i>ORR</i>	<i>Overall response rate</i>
<i>OS</i>	<i>Overall survival</i>
<i>PDAC</i>	<i>Pancreatic adenocarcinoma</i>
<i>PEN2</i>	<i>Presenilin enhancer 2</i>
<i>PFS</i>	<i>Progression-free survival</i>
<i>PI3K</i>	<i>phosphoinositide 3-kinase</i>
<i>PS</i>	<i>Presenilin</i>
<i>R/R</i>	<i>Relapsed / refractory</i>
<i>RB1</i>	<i>Retinoblastoma gene</i>
<i>RIC</i>	<i>Reduced intensity conditioning</i>
<i>RS</i>	<i>Richter syndrome</i>
<i>SEER</i>	<i>Surveillance, Epidemiology, and End Results Program</i>
<i>TLS</i>	<i>Tumor lysis syndrome</i>
<i>UVB</i>	<i>Ultraviolet rays effects</i>
<i>W&W</i>	<i>Watch and wait</i>

INTRODUCTION

Gamma secretases are intramembranous multisubunit protease complexes that are composed of four core components (presenilin, nicastrin, presenilin enhancer 2 (Pen2) and anterior pharynx-defective 1 (Aph1), and several associated proteins (*De Strooper and Annaert, 2010*).

Two presenilin genes and two Aph genes have been identified in the human genome, so there could be at least 6 different gamma secretase complexes containing different presenilin as Aph1 could exhibit distinct activities (*Serneels et al., 2009*).

Gamma secretase was primarily identified in Alzheimer's disease as it cleaves amyloid precursor protein (APP) (*Laguarta, and Pera, 2010*).

Gamma secretase cleaves various type 1 membrane proteins by regulated intramembrane proteolysis. The gamma secretase mediated cleavage releases the C terminal intracellular domain (ICD) of the substrate protein which may perform important signaling functions inside the cells. The group of gamma secretase substrates is large and constantly growing (*Haapasalo and Kovacs, 2011*).

Many of the identified substrates are intimately involved in tumorigenesis. Those substrates as NOTCH receptors and their ligands, CD 44, ErbB4, E-cadherin, and MUC1. Gamma

secretase may influence on tumorigenic also via its role in angiogenesis as many of substrates are shown to regulate the formation and development of new blood vessels (**Boulton et al., 2008**).

Many of physiological and pathological activities of gamma secretase is derived from its activity as a protease against NOTCH, a central molecule in the control of growth and differentiation (**De Strooper et al., 1999**).

NOTCH activation plays an important role in the genesis of T cell acute lymphoblastic leukemia (**Weng et al., 2004**).

In contrast, the role of NOTCH activation in B cell malignancies is not clear (**Chiaramonte et al., 2003**).

However, follicular dendritic cells leaving NOTCH legand activate NOTCH and protect germinal center B cells from apoptosis (**Yoon et al., 2009**).

There are several reports of NOTCH activation in Hodgkin's lymphoma, multiple myeloma and chronic B cell lymphocytic leukemia (**Jundt et al., 2002; Nefedova et al., 2008 and Rosati et al., 2009**).

Due to the central role of gamma secretes in these malignancies, considerable efforts have been made to characterize this unique protease, however, to the best of our

knowledge, all the studies were directed to an exo cell assay of gamma secretase expression and activity and even in vitro inhibition of gamma secretase activity in some cell lines of B cell malignancies (*Shelton et al., 2009; Ramakrishnan et al., 2012 and Secchiero et al., 2017*).

So, modulation or inhibition of gamma secretase activity and hence altered signal pathways, could be a light path as a line of therapy against various types of tumor cells (*Selkoe and Walfe, 2007; Shih and Wang, 2007 and Groth and Fortini, 2012*).

Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5⁺CD23⁺ B cells in the peripheral blood, secondary lymphoid tissues and bone marrow. CLL is an incurable disease with a heterogeneous clinical course, for which the treatment decision still relies on conventional parameters (such as clinical stage and lymphocyte doubling time) (*Bosch and Dalla-Favera, 2019*).

AIM OF THE WORK

The Aim of this work is to evaluate the in vivo expression of gamma secretase catalytic subunit (Presenilin) in patients with B cell lymphocytic leukemia.

Chapter 1**CHRONIC LYMPHOCYTIC LEUKEMIA**

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults and mainly affects the elderly (*Zenz et al., 2010*).

CLL is a B cell malignancy, where clonal CD5+CD19+CD23+ B cells accumulate in peripheral blood and infiltrate secondary lymphoid organs such as lymph nodes, spleen, and bone marrow (*Stilgenbauer et al. 2014*). The disease is highly heterogeneous clinically mostly due to hyper mutations of the immunoglobulin heavy-chain genes (IGHV), genomic aberrations, and recurrent gene mutations which associate with the clinical course.

Epidemiology

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program (SEER), the estimated number of new cases of CLL in the United States in 2018 was 20,940, representing 1.2% of new cancer diagnoses and the number of deaths from CLL was 4510. 7% of all cancer deaths (SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia, National Cancer Institute, Bethesda, MD. Median age at diagnosis was 70, with the highest numbers of cases identified in the 65–74 yr age group.